Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

2 Red Flags for Gilead Sciences' Future

TheMotleyFool

0 0

2 Red Flags for Gilead Sciences' FuturePhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png

It hasn't been a great year for biotech giant Gilead Sciences (NASDAQ: GILD). The company's shares are down by 15% since the year started, which is more or less in line with the bad performance of the broader market.

It would be easy to pin the biotech's recent struggles on the volatile geopolitical environment and the various economic issues we're facing. Unfortunately, there are company-specific headwinds investors should worry about too.

Let's consider two of these red flags and whether it's worth purchasing shares of Gilead Sciences anyway.

Source Fool.com

Like: 0

GILD

Teilen